MedTrace Logo

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

NCT00384852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2013-02-28

No results posted yet for this study

Summary

The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and a single dose of rhBMP-2/CPM compared to subjects who receive standard of care alone.

Conditions

  • Fractures

Interventions

DRUG

rhBMP-2/CPM

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • Finland
  • France
  • Germany
  • Mexico
  • Norway
  • Romania
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384852 on ClinicalTrials.gov